[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Anhui Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":563},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,40,66,95,125,154,178,199,226,254,273,298,322,341,362,383,408,431,449,474,493,515,540],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100641317","anti-inflammatory-dietary-intervention-in-patients-with-type-2-diabetes-a-randomized-controlled-trial-100641317",false,"NCT07656805","Anti-inflammatory Dietary Intervention in Patients With Type 2 Diabetes: A Randomized Controlled Trial","Evidence-based Construction and Application of an Anti-inflammatory Diet Intervention for Patients With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n1. Patients who meet the diagnostic criteria for type 2 diabetes mellitus (T2DM) according to the Guidelines for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2020 Edition);\n2. Aged 18 years or older;\n3. Able and willing to complete all study questionnaires;\n4. Willing to provide blood samples for laboratory testing;\n5. Possessing adequate communication and comprehension abilities, with no impairment of consciousness, and able to respond to investigators' questions;\n6. Willing to participate in regular follow-up visits and assessments according to the study protocol and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients with a history of diseases affecting blood glucose metabolism, such as hyperthyroidism or Cushing's syndrome;\n2. Pregnant or breastfeeding women;\n3. Patients with severe hepatic dysfunction, renal dysfunction, heart failure, or malignant tumors;\n4. Patients with acute or chronic infectious diseases accompanied by obvious signs of infection, including clinically diagnosed intestinal infections, respiratory tract infections, periodontitis, and other infectious conditions;\n5. A history of recent use of medications that may affect inflammatory or metabolic status, such as nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin) or glucocorticoids;\n6. Patients who have undergone gastrointestinal surgery or have diseases that may affect the effectiveness of dietary intervention, such as malabsorption syndrome.","ALL","18 Years",{"count":19,"type":20},88,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate whether an evidence-based anti-inflammatory dietary intervention can reduce inflammation and improve glycemic control in patients with type 2 diabetes mellitus (T2DM). T2DM is a chronic metabolic disease characterized by elevated blood glucose levels and is closely associated with chronic low-grade inflammation.\n\nThe main questions it aims to answer are:\n\nDoes an anti-inflammatory dietary intervention reduce levels of hs-CRP, a key marker of chronic inflammation, in patients with T2DM? Does the intervention improve dietary inflammatory index (DII) scores and glycemic outcomes, including fasting blood glucose and 2-hour postprandial blood glucose? Researchers will compare an anti-inflammatory diet intervention group to a standard diabetes dietary control group to determine whether the anti-inflammatory dietary pattern provides additional benefits beyond routine dietary management.\n\nParticipants will:\n\nBe randomly assigned to either the anti-inflammatory diet group or the standard diabetes diet group Receive dietary guidance based on structured anti-inflammatory food recommendations or routine diabetes dietary advice Complete dietary assessments, including 24-hour dietary recalls to calculate dietary inflammatory index (DII) Provide blood samples to measure hs-CRP, fasting blood glucose, and 2-hour postprandial blood glucose at baseline and after 4 weeks Complete questionnaires on dietary adherence and quality of life Participate in a 4-week intervention period with follow-up assessments",[26],"T2DM (Type 2 Diabetes Mellitus)","RECRUITING","2026-06-14",{"date":30,"type":31},"2026-06-18","ACTUAL",{"date":33,"type":31},"2026-06-03",{"date":35,"type":20},"2026-11",{"name":37,"class":38},"Anhui Medical University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100639345","classroom-physical-activity-in-university-students-100639345","NCT07594457","Classroom Physical Activity in University Students","The Effects of Classroom-based Physical Activity on Academic Self-efficacy in University Students","Inclusion Criteria:\n\n* Full-time university students aged 18-26 years\n* Able to stand and walk independently\n* Willing to participate in the 8-week intervention and assessments\n\nExclusion Criteria:\n\n* Self-reported history of lower extremity injury or surgery in the past 6 months\n* Diagnosed neurological or vestibular disorders affecting balance\n* Regular participation in structured balance or physical activity training outside the study\n* Any medical condition that prevents safe performance of physical activity",true,"26 Years",{"count":50,"type":20},80,[23],"The goal of this study is to learn if a classroom-based physical activity program can improve academic self-efficacy in university students.\n\nThe main question it aims to answer is: Do students who take part in classroom-based physical activities have higher academic self-efficacy scores than students who do not? Researchers will compare students in classrooms that do the physical activity program to students in classrooms that continue their usual class routine (no extra activities).\n\nParticipants will:\n\nIf in the activity group: take part in one time per day, five times a week, a total of eight weeks during regular classes.\n\nIf in the control group: attend classes as normal. Complete a questionnaire about their academic self-efficacy.",[54],"Academic Self-efficacy",[56],"classroom based physical activity","NOT_YET_RECRUITING","2026-05-17",{"date":60,"type":31},"2026-05-20",{"date":62,"type":20},"2026-09-01",{"date":64,"type":20},"2026-12-30",{"name":37,"class":38},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":39},"100630371","effects-of-tavns-combined-with-tacs-on-adolescents-with-non-suicidal-self-injury-100630371","NCT07486804","Effects of taVNS Combined With tACS on Adolescents With Non-Suicidal Self-Injury","Effects of Combined taVNS and tACS on Adolescents With Non-Suicidal Self-Injury: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Meet the proposed diagnostic criteria for non-suicidal self-injury (NSSI) in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), with ≥5 documented self-injury episodes and at least one incident within the past month as assessed by the Adolescent Non-Suicidal Self-Injury Assessment Questionnaire (ANSAQ)\n* Aged 12-18 years\n* Right-handed\n* Possess formal education experience sufficient to comprehend experimental protocols\n* Normal or corrected-to-normal binocular visual acuity\n* Voluntarily participate with legal guardians providing written informed consent\n\nExclusion Criteria:\n\n* Montreal Cognitive Assessment (MoCA) score \\\u003C 26\n* History of suicide attempts\n* History of epilepsy, brain surgery, tumors, or clinically significant head trauma\n* History of substance abuse or severe physical diseases\n* Received physical or psychological interventions within the past three months","12 Years","22 Years",{"count":76,"type":20},90,[23],"NSSI behavior is highly prevalent among adolescents, and its mechanisms are closely associated with attentional bias toward self-injury-related information and impulsivity, both of which may be related to reduced dlPFC activation levels. Introducing taVNS as a priming stimulus to pre-regulate brain state and optimize subsequent tACS treatment response provides a novel approach to addressing inconsistent intervention effects. Simultaneously, this facilitates a shift in the brain from passive stimulus reception to active state regulation, offering important theoretical foundations for developing more precise and efficient cross-modal neuromodulation therapies.This study aims to systematically validate the efficacy of a combined protocol using taVNS as a priming modality followed by tACS over the left dlPFC through a randomized controlled trial (RCT). The investigators hypothesize that:\n\n① Compared to tACS intervention alone, this combined approach will not only demonstrate non-inferiority in overall therapeutic efficacy but, more importantly, significantly reduce inter-individual variability in treatment response to tACS. This would mitigate the issue of high clinical response heterogeneity and enhance the stability and predictability of treatment outcomes.\n\n② Early behavioral biomarkers of intervention response are anticipated: Immediate improvements in attentional bias following a single combined intervention session will significantly predict reductions in the frequency and intensity of Non-Suicidal Self-Injury (NSSI) after a full course (14 sessions) of treatment. This suggests that early positive changes in cognitive function could serve as valid indicators predicting long-term clinical efficacy, offering a critical time window for implementing individualized treatment adjustments.\n\n③ The study will elucidate the effects of the taVNS-primed combined tACS treatment on neuroimaging mechanisms in adolescents with NSSI.",[80],"Non-suicidal Self-injury",[82,83,84,85,86],"non-suicidal self-injury","transcranial alternating current stimulation","taVNS","tACS","state-dependant","2026-03-19",{"date":89,"type":31},"2026-03-23",{"date":91,"type":31},"2025-10-16",{"date":93,"type":20},"2027-10-01",{"name":37,"class":38},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":39},"100623973","mapsd-dual-target-ctbs-auditory-cortex-and-m1-for-generalized-anxiety-disorder-100623973","NCT07403591","Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder","Efficacy and Neural Mechanisms of Neuroimage-guided Dual-target Continuous Theta Burst Stimulation (Auditory Cortex and M1) for Generalized Anxiety Disorder","Dual-ACM1-GAD","Inclusion Criteria:\n\n1. Diagnosis of Generalized Anxiety Disorder (GAD) according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), confirmed by at least two psychiatrists.\n2. Hamilton Anxiety Rating Scale (HAMA) score \\> 14.\n3. Age between 18 and 60 years.\n4. Right-handed.\n5. More than 5 years of education.\n6. Patients are either medication-free or maintain a consistent medication regimen during cTBS treatment.\n7. Willing and able to provide written informed consent.\n8. Normal or corrected-to-normal visual acuity and hearing.\n\nExclusion Criteria:\n\n1. Presence of other psychiatric disorders, such as substance abuse, schizophrenia, schizoaffective disorder, hysteria, autism, or bipolar disorder.\n2. History of epilepsy, seizures, or severe neurological diseases (e.g., stroke, organic brain lesions).\n3. Presence of severe somatic diseases, such as severe heart, liver, or renal insufficiency.\n4. Pregnant or lactating women.\n5. Contraindications to Transcranial Magnetic Stimulation (TMS) or Magnetic Resonance Imaging (MRI), such as the presence of a cardiac pacemaker, cochlear implant, cerebrovascular metal stent, or metal dentures.\n6. Inability to cooperate with experimental procedures due to conditions such as severe claustrophobia.","60 Years",{"count":105,"type":20},60,[23],"The purpose of this study is to investigate the effectiveness of a dual-target non-invasive brain stimulation technique called continuous Theta Burst Stimulation (cTBS) for treating Generalized Anxiety Disorder (GAD). The researchers will use a neuronavigation system, which acts like a GPS for the brain, to guide the stimulation to two specific targets: the left auditory association cortex and the primary motor cortex (M1).\n\nParticipants will be randomly assigned to one of two groups. One group will receive active dual-target cTBS treatment, while the other will receive a sham (placebo) stimulation that feels similar but has no therapeutic effect. The treatment will be given three times a day for seven consecutive days. Before and after the treatment period, all participants will complete clinical questionnaires to measure their anxiety and undergo Magnetic Resonance Imaging (MRI) scans to help researchers understand how cTBS affects brain activity.",[109],"Generalized Anxiety Disorder",[109,111,112,113,114,115,116],"Continuous Theta Burst Stimulation","Transcranial Magnetic Stimulation","Neuronavigation","Dual-target","Auditory Cortex","Primary Motor Cortex","2026-02-04",{"date":119,"type":31},"2026-02-11",{"date":121,"type":20},"2026-03-01",{"date":123,"type":20},"2027-04-01",{"name":37,"class":38},{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":132,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":136,"studyType":137,"phases":4,"briefSummary":138,"conditions":139,"keywords":143,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":39},"100601600","study-of-predicting-lymph-node-metastasis-of-high-risk-prostate-cancer-by-artificial-intelligence-multi-omics-analysis-100601600","NCT07112599","Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis","Clinical Study on Predicting Lymph Node Metastasis of High-risk Prostate Cancer Based on Artificial Intelligence Multi-omics Analysis：A Multicenter, Prospective and Observational Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 50 years\n2. Patients must have histologically or cytologically confirmed prostate adenocarcinoma\n3. PSA ≥ 20ng\u002Fml or Gleason ≥ 8\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-2\n5. Life expectancy ≥ 6 months\n6. Normal bone marrow function: absolute neutrophil count ≥ 1.5×109\u002FL; platelets ≥ 75×109\u002FL; hemoglobin ≥ 90g\u002FL; white blood cell count ≥ 3.0×109\u002FL\n7. Normal liver function: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal (ULN); for patients with liver metastasis, ALT\u002FAST can be ≤ 5 times ULN\n8. Total bilirubin ≤ 1.5 times ULN or total bilirubin \\> 1.5 times ULN and direct bilirubin ≤ ULN;\n9. Normal coagulation function: International Normalized Ratio（INR） ≤ 1.5, partial thromboplastin time (APTT) ≤ 1.5 times ULN, prothrombin time (PT) \\\u003C ULN + 4 seconds\n10. Normal heart function: left ventricular ejection fraction (LVEF) ≥ 50%; corrected QT interval male \\\u003C 450ms, female \\\u003C 470ms, serum potassium ≥ 3.5mmol\u002FL\n11. Normal blood pressure: systolic blood pressure \\\u003C 140mmHg, diastolic blood pressure \\\u003C 90mmHg; patients with stable blood pressure assessment after appropriate clinical treatment can be enrolled\n12. Normal renal function: serum creatinine ≤ 1.5 times ULN, and creatinine clearance ≥ 50 mL\u002Fmin\n13. Prospective subjects can understand and are willing to sign the informed consent form\n14. Able to comply with the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\n1. Patients with contraindications to MRI examination, such as metal implants in the body, claustrophobia, etc.\n2. Patients with any missing baseline clinical and pathological information\n3. Patients with a clear history of neurological and psychiatric disorders, such as dementia, epilepsy, or seizures\n4. In the judgment of the investigator, there are serious concomitant diseases that endanger the safety of the subjects or affect the subjects' completion of this study (such as severe diabetes, thyroid disease, and mental illness, etc.), or factors that affect the safety of the patients or affect the patients' provision of informed consent (including laboratory abnormalities), or any psychological, family, sociological or geographical conditions that affect the study plan and follow-up plan\n5. The investigator believes that it is not suitable to participate in this clinical trial for any reason\n6. Unable to provide informed consent","MALE","50 Years",{"count":135,"type":20},2000,"1 Month","OBSERVATIONAL","The pathological-omics and imaging-omics in this study are combined to construct an artificial intelligence (AI) model that can predict whether high-risk prostate cancer patients may have lymph node metastasis. The model determines whether the patient has lymph node metastasis based on the MRI results and the pathological section image information of the case combined with clinical data before radical resection of the prostate. This study is a multicenter, prospective clinical study to verify the model's ability to predict whether high-risk prostate cancer patients may have lymph node metastasis.",[140,141,142],"Prostate Cancer","Lymph Node Cancer Metastatic","Artificial Intelligence (AI)",[144,145],"prostate cancer","AI","2026-01-08",{"date":148,"type":31},"2026-01-09",{"date":150,"type":20},"2026-01-25",{"date":152,"type":20},"2027-06-30",{"name":37,"class":38},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":132,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100601601","minimal-residual-disease-used-in-predicting-therapeutic-efficacy-in-metastatic-hormone-sensitive-prostate-cancer-100601601","NCT07112612","Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer","Application of Personalized Minimal Residual Disease in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer","Inclusion Criteria:\n\n1. Aged 18 years and younger than 85 years;\n2. Patients diagnosed with prostate acinar adenocarcinoma, ductal adenocarcinoma, or intraductal carcinoma by pathological histology;\n3. Patients with clear distant metastases found by imaging (in accordance with RECIST criteria);\n4. Patients with locally advanced (N1) and metastatic (M1) prostate cancer at diagnosis.\n5. Patients who have not received endocrine therapy or other systemic anti-tumor treatments in the past;\n6. ECOG score of 0-2 points, with an expected survival period of more than 6 months;\n7. Patients with normal organ function;\n8. Routine blood test (no blood transfusion or blood products within 14 days):\n\n   Hemoglobin (HGB) ≥ 90g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL (1500 \u002Fmm3); Platelet count (PLT) ≥ 75×109\u002FL; White blood cell count (WBC) ≥ 3×109\u002FL;\n9. Biochemical examination:\n\n   Total bilirubin (TBIL) ≤ upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 ULN; Creatinine clearance (CCr) ≥ 30ml\u002Fmin; (Cockcroft-Gault formula);\n10. Coagulation function: prothrombin international normalized ratio (INR) ≤ 1.5 or prothrombin time (PT) \\\u003C 4 seconds;\n11. Patients agree to sign informed consent and are able to attend scheduled study visits, provide clinical information, and cooperate with other study procedures.\n\nExclusion Criteria:\n\n* (1) Patients diagnosed with neuroendocrine\u002Fsmall cell prostate cancer by pathological histology; (2) No clear distant metastasis was found by imaging (in accordance with RECIST criteria); (3) Patients with a history of previous treatment: including neoadjuvant and adjuvant therapy; (4) The samples submitted for examination failed to meet the quality control requirements.\n\n  (5) Patients with combined endocrine, metabolic system diseases or other serious digestive system diseases; (6) Patients with combined chronic hepatitis, cirrhosis, chronic nephritis, renal insufficiency and other diseases; (7) Patients with a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; (8) Patients with a history of other malignant tumors; (9) Patients enrolled in other clinical trials; (10) Patients unable to obtain the clinical information required for the study (e.g., patients lost to follow-up); (11) Other situations that the researchers consider unsuitable for enrollment.","85 Years",{"count":163,"type":20},50,"This study is a prospective, single-center, observational study of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Minimal residual disease (MRD) detection is used to investigate the actual efficacy responses of mHSPC patients with different gene mutation characteristics to treatment regimens. Factors influencing efficacy are further analyzed to provide a basis for the precise clinical diagnosis and treatment of mHSPC patients.",[166,140,167],"MRD","mHSPC",[169,166,170],"minimal residual disease","PCa",{"date":172,"type":31},"2026-01-12",{"date":174,"type":20},"2026-01-30",{"date":176,"type":20},"2027-04-30",{"name":37,"class":38},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":21,"phases":188,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":39},"100618363","phase-2-prospective-clinical-trial-of-crisugabalin-capsules-in-the-treatment-of-generalized-anxiety-disorder-100618363","NCT07330648","Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder","Evaluation of the Efficacy and Safety of Crisugabalin Capsules Versus Placebo and Venlafaxine Extended-Release (XR) Capsules in Chinese Patients With Generalized Anxiety Disorder: A Prospective, Multicenter, Randomized, Double-Blind, Double-Dummy, Active- and Placebo-Controlled Clinical Trial.","CEASE-GAD","Inclusion Criteria:\n\n* Able to understand and voluntarily participate in the trial, and provide written informed consent form (ICF);\n* Male or female aged ≥18 years (inclusive of the threshold value);\n* Met the diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for generalized anxiety disorder (GAD) and confirmed by the Brief International Neuropsychiatric Interview (M.I.N.I.);\n* Require pharmacological treatment for psychiatric symptoms;\n* Hamilton Anxiety Scale (HAMA) score ≥20, Hamilton Depression Scale (HAMD-17) score ≤2, Clinical Global Impression Scale (CGI-S) score ≥4 at screening and baseline Points;\n\nExclusion Criteria:\n\n* subjects with serious suicide risk at present, or HAMD-17 item 3-suicide score ≥3;\n* subjects with HAMD-17 \\> 17;\n* subjects whose HAMA scores decreased by ≥20% in the baseline period compared with the screening period:\n* Those who met the DSM-5 diagnostic criteria for other mental disorders except GAD;\n* subjects with previous history of depression, obsessive-compulsive disorder, bipolar disorder, psychotic disorder, factitious disorder and somatoform disorder; There were severe personality disorders, especially antisocial, borderline, or histrionic personality disorder, which were judged by the investigator to affect the patient's adherence to the study protocol;\n* Alcohol or drug abuse or dependence within 180 days before screening;\n* With severe or unstable has clinical significance of somatic disease, including any cardiovascular, cancer, kidney, respiratory, endocrine (including abnormal thyroid function), digestion, blood (such as with bleeding tendency) or nervous system diseases;\n* History of inadequate response to at least two prior antidepressant drugs and\u002For benzodiazepines after adequate dose and duration of treatment (i.e., at least 4 weeks at a clinically appropriate dose), or failure to achieve sufficient clinical efficacy with pregabalin ≥300 mg\u002Fday (i.e., subject-reported insufficient response or lack of meaningful clinical improvement).\n* History of severe hypersensitivity reactions (e.g., anaphylaxis) or allergies to at least two classes of drugs (including photosensitivity), or known hypersensitivity to pregabalin, the investigational drug, structurally related compounds, or any of their excipients.\n* subjects whose physical examination or vital signs were abnormal and clinically significant (e.g. inadequately controlled hypertension, systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg);\n* subjects with a history of epilepsy or any other disease that may induce seizures, except convulsions caused by febrile convulsions in children;\n* Severe hematologic, hepatic or renal dysfunction during the screening period, the subject will be excluded if: a. Neutrophils \\\u003C 1.5 × 10\\^9\u002FL, or platelet \\\u003C 90 × 10\\^9\u002FL, or hemoglobin \\\u003C 100 g\u002FL; b. AST\u002FALT \\> 2.5 × upper limit of normal (ULN), or TBIL \\> 1.5 × ULN; c. Estimation of glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin \u002F 1.73 m\\^2; d. Creatine kinase \\> 2.0 × ULN.\n* Clinically significant abnormalities on electrocardiography (QT interval corrected by Fridericia method: ≥450 ms for men or ≥470 ms for women) or conditions deemed ineligible by the investigators;\n* Subjects who had undergone psychiatric surgery, electroconvulsive therapy or transcranial magnetic stimulation within 90 days before screening;\n* Use of β-blockers within 90 days prior to screening with an ongoing need for continued treatment;\n* Receiving systemic psychotherapy or other non-pharmacological treatments (e.g., acupuncture, hypnosis, or phototherapy) within 6 weeks before the baseline visit;\n* Subjects with dysphagia or inability to tolerate oral medications.\n* Subjects with active gastrointestinal disorders (including any history of gastrointestinal surgery) that, in the investigator's judgment, may interfere with the absorption of the investigational drug.\n* Those who had used benzodiazepines within -7 to -1 days before screening, such as lorazepam, oxazepam, and alprazolam for less than 5 half-lives; The use of benzodiazepines with longer half-lives, such as diazepam, clonazepam, nitrazepam, estazolam, and flurazepam, not more than 5 half-lives or less than 30 days from the screening period, or the use of barbiturates not more than 5 half-lives or less than 30 days from the screening period;\n* Patients who discontinued traditional Chinese medicine, melatonin, and St. John's wort for less than 3 days before the baseline visit;\n* Pregnant or preparing for pregnancy or breastfeeding during the study period, or subjects were not willing to use reliable contraceptives methods from the date of ICF signature until 28 days after the last trial drug administration, or planning to use progesterone contraceptives during this period;\n* Individuals engaged in potentially hazardous mechanical operations such as working at heights or operating motor vehicles.\n* Participants enrolled in other clinical trials within 30 days before screening;\n* Subjects with other conditions deemed by the investigator to be ineligible for enrollment.",{"count":187,"type":20},216,[189],"PHASE2","A placebo-controlled superiority design was used to evaluate the efficacy of 40 mg\u002F day of Crisugabalin capsules in the treatment of GAD.",[109],"2025-12-29",{"date":148,"type":31},{"date":195,"type":31},"2025-10-10",{"date":197,"type":20},"2027-02-28",{"name":37,"class":38},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":225},"100606508","personalized-itbs-in-real-world-clinical-settings-for-schizophrenia-100606508","NCT07176468","Personalized iTBS in Real-World Clinical Settings for Schizophrenia","Efficacy of Personalized iTBS in Real-World Clinical Settings for Alleviating Schizophrenia Symptoms : A Randomized Single-Blind Trial","EPSREAL-SC","Inclusion Criteria:\n\n* Aged 18-60 years, any gender\n* Meets DSM-5 criteria for schizophrenia\n* Antipsychotic medication change (initiation, dose adjustment, or switch) occurred within the past 3 days\n* Capable of understanding the study and providing written informed consent Able to comply with study procedures and complete assessments\n\nExclusion Criteria:\n\n* Active suicidal ideation or behavior\n* Major neurological disorders (e.g., epilepsy, organic brain lesions, severe head trauma)\n* Contraindications to MRI or TMS (e.g., metal implants, pacemakers)\n* Pregnancy or lactation\n* Receipt of TMS or ECT within the past 6 months\n* Judged by investigators to be unsuitable for participation",{"count":208,"type":20},40,[23],"This study is designed to determine whether neuronavigation-guided, personalized Intermittent Theta-Burst Stimulation (iTBS) can produce clinically benefits for patients with schizophrenia when delivered in real-world treatment settings. By situating the intervention within real-world treatment settings-without imposing restrictions on concurrent pharmacotherapy-this trial seeks to generate evidence that is both scientifically rigorous and clinically relevant.\n\nThe main questions it seeks to address are:\n\nDoes the personalized iTBS target TMS protocol improve clinical symptoms in patients with schizophrenia within real-world treatment settings? What neural circuit changes, as assessed by functional MRI, occur following TMS treatment?\n\nParticipants will:\n\nUndergo personalized,personalized iTBS target treatment daily for 2 weeks. Complete baseline and post-treatment assessments, including clinical symptom scales (PANSS, HAMA, HAMD) and neuropsychological tests (MoCA, DST, VFT, Stroop Test, and AVLT).\n\nHave structural and resting-state functional MRI scans before and after treatment.\n\nBe monitored for any treatment-related adverse events.",[212,112],"Schizophrenia",[214,215,216],"schizophrenia","transcranial magnetic stimulation","Functional Magnetic Resonance Imaging (fMRI)","2025-12-28",{"date":219,"type":31},"2025-12-30",{"date":221,"type":31},"2025-10-20",{"date":223,"type":20},"2026-09-20",{"name":37,"class":38},2,{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":236,"briefSummary":237,"conditions":238,"keywords":243,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":39},"100602088","respiratory-gated-transcutaneous-auricular-vagus-nerve-stimulation-for-improving-apathy-in-parkinsons-disease-100602088","NCT07118956","Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease","Respiratory-gated Transcutaneous Auricular Vagus Nerve Stimulation for Improving Apathy in Parkinson's Disease: A Randomized, Double-blind, Sham-controlled Trial","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for idiopathic Parkinson's disease (based on the MDS Clinical Diagnostic Criteria for Parkinson's Disease (2015 version)).\n2. Patients with Apathy Motivation Index (AMI) score \\>1.7.\n3. All PD patients must be on stable, standardized medication regimens with no adjustments to medications for at least 1 month prior to the study and throughout the study period.\n4. Demonstrate good compliance and adherence, capable of completing behavioral tests and taVNS therapy.\n5. Mini-Mental State Examination (MMSE) score ≥22.\n6. Meet safety criteria for MRI screening.\n\nExclusion Criteria:\n\n1. Prior brain MRI\u002FCT showing focal brain lesions or severe white matter disease (Fazekas grade 3 or higher).\n2. Secondary parkinsonism (e.g., vascular parkinsonism, drug-induced parkinsonism).\n3. History of severe traumatic brain injury, neurosurgery, or deep brain stimulation (DBS) therapy.\n4. Personal history of epilepsy, unexplained loss of consciousness, or current use of anticonvulsant medications for seizure control.\n5. Diagnosis of neuropsychiatric disorders other than Parkinson's disease.\n6. Current use of non-steroidal anti-inflammatory drugs (NSAIDs) or Non-benzodiazepine GABA receptor agonist drug or anticholinergics or corticosteroids, or history of substance abuse or drug addiction.\n7. Participation in any clinical trial within the past 3 months.\n8. Severe systemic comorbidities (e.g., hepatic\u002Frenal failure, arrhythmias, organic heart disease).\n9. Pregnant\u002Flactating women or subjects (including males) planning pregnancy within 6 months.\n10. Contraindications to taVNS, such as cardiac pacemakers, post-DBS surgery, or auricular pathologies (e.g., tympanic membrane perforation).","40 Years","90 Years",{"count":105,"type":20},[23],"The goal of this clinical trial is to learn whether 100HZ respiratory-gated vagus nerve stimulation (RAVANS) can improve the non-motor symptoms in people with Parkinson's disease (PD). It will also learn the safety of 100HZ RAVANS. The main questions it aims to answer are:\n\nCan 100HZ RAVANS improve apathy in people with PD? Did the participants have any side effects or safety issues when undergoing 100HZ RAVANS? Researchers compared 100HZ RAVANS with sham stimulation (low-dose stimulation of the same site and treatment parameters) to see if 100HZ RAVANS could improve non-motor symptoms in patients with PD.\n\nParticipants will:\n\nReceive 100HZ RAVANS or sham stimulation for 2 weeks. Neuropsychological assessment, imaging and biological sample collection were conducted before and after the entire cycle.",[239,240,241,242],"Parkinson Disease","Apathy","Non-motor Symptoms","Vagus Nerve Stimulation",[239,240,244,245],"Non-motor symptoms","Transcutaneous Auricular Vagus Nerve Stimulation","2025-11-17",{"date":248,"type":31},"2025-11-19",{"date":250,"type":31},"2025-05-01",{"date":252,"type":20},"2028-05-01",{"name":37,"class":38},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":233,"maxAge":161,"enrollmentInfo":260,"targetDuration":4,"studyType":21,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":39},"100454070","effect-of-theta-burst-transcranial-magnetic-stimulation-tbs-for-freezing-of-gait-100454070","NCT05192759","Effect of Theta-Burst Transcranial Magnetic Stimulation (TBS) for Freezing of Gait","Inclusion Criteria:\n\n1. diagnosis of FOG with expertise in movement disorders.\n2. the score of item 3 of the FOG questionnaire ≥1.\n3. ongoing treatment with a stable dose of any medication for 2 months.\n4. 40 years of age or older.\n\nExclusion Criteria:\n\n1. a history of addiction, psychiatric disorders, or neurological diseases other than PD.\n2. focal brain lesions on T1-\u002FT2-weighted fluid-attenuated inversion recovery images.\n3. anti-PD medication adjustments during rTMS treatment.\n4. history of substance abuse within the past 6 months.\n5. nonremovable metal objects in or around the head.\n6. previously received rTMS treatment.\n7. prior history of seizure or history in first-degree relatives.",{"count":208,"type":20},[23],"To investigate the treatment effect of Theta-burst Transcranial Magnetic Stimulation (TBS) on patients with freezing of gait (FOG) and the underlying neural mechanism.",[112,264],"Freezing of Gait",[112,266],"Freezing of gait",{"date":248,"type":31},{"date":269,"type":31},"2021-11-22",{"date":271,"type":20},"2028-12-30",{"name":37,"class":38},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":280,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":21,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":225},"100597066","effect-of-vitamin-d-on-cardiovascular-metabolic-risk-in-overweightobesity-adolescents-in-china-100597066","NCT07053657","Effect of Vitamin D on Cardiovascular Metabolic Risk in Overweight\u002FObesity Adolescents in China","The Improvement Effect of Vitamin D on the Cardiovascular Health of Overweight\u002FObesity Adolescents in China","Inclusion Criteria:\n\n1. Students whose caregivers signed informed consents;\n2. Students with serum 25(OH)D concentration of 12-20 ng\u002FmL;\n3. Students with overweight or obesity.\n\nExclusion Criteria:\n\n1. Students with any disease that affects vitamin D metabolism (e.g., functional\u002Forganic brain disease, severe infectious disease, chronic gastrointestinal disease, hepatic or renal insufficiency, etc.);\n2. Students with known chronic disease (e.g., cardiovascular disease); use of vitamin D supplements in the past 3 months;\n3. Students with allergies to vitamin D or soybean oil ingredients.","10 Years","16 Years",{"count":283,"type":20},130,[23],"The goal of this randomized controlled clinical trial is to investigate the effects of vitamin D3 supplementation on cardiometabolic risk in Chinese adolescents with overweight\u002Fobesity and vitamin D deficiency. The main question it aims to answer whether vitamin D3 supplementation can improve cardiovascular metabolic health.\n\nParticipants in the intervention group will receive vitamin D3. The control group will receive vitamin D placebo.\n\nResearchers will compare the change in cardiometabolic risk from baseline to post-intervention at 12 weeks between the intervention and control groups.",[287],"Cardiometabolic Risk Factors",[289,290],"cardiometabolic risk","vitamin D","2025-11-14",{"date":246,"type":31},{"date":294,"type":31},"2025-09-15",{"date":296,"type":20},"2025-12-31",{"name":37,"class":38},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":308,"conditions":309,"keywords":313,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":39},"100541923","cognitive-decline-and-underlying-mechanisms-in-symptomatic-intracranial-artery-stenosis-patients-a-cohort-study-100541923","NCT06336174","Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study","Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Atherosclerotic Stenosis Patients: A Multicenter Cohort Study","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Severe stenosis (≥70%-99%) of atherosclerotic internal carotid artery (C6 segment, C7 segment) or middle cerebral artery (M1 segment) confirmed by digital subtraction angiography (DSA) or at least two of the following non-invasive examinations: magnetic resonance angiography (MRA), computed tomography angiography (CTA), or transcranial Doppler (TCD)\n* Transient ischemic attack (TIA) or minor stroke (National Institute of Health Stroke Scale \\[NIHSS\\] score ≤ 4 points)\n* Right-handed and able to cooperate in neuropsychological tests\n* At least 14 days post-onset of cerebral infarction or TIA\n* Signed informed consent\n\nExclusion Criteria:\n\n* Other diseases that affect cognitive function, such as cerebral hemorrhage, •Parkinson's disease, neurosyphilis, dementia, tumors, etc.\n* Right upper limb hemiplegia, aphasia, visual field defects, or visual impairments\n* More than 50% stenosis of the extracranial internal carotid artery, the vertebral artery, or the basilar artery\n* Vasculitis, moyamoya disease, and cardiogenic stroke\n* Previous history of head and neck stent implantation, carotid endarterectomy, aneurysm embolization, or other intracranial surgeries","80 Years",{"count":307,"type":20},100,"The purpose of this study is to explore the mechanism of cognitive impairment in patients with symptomatic intracranial atherosclerotic stenosis (ICAS), and further plans to explore the impact of different treatment options on cognitive function in symptomatic ICAS patients.",[310,311,312],"Intracranial Atherosclerosis","Cognitive Impairment","Cerebrovascular Event",[314,311,315],"Symptomatic Intracranial Atherosclerosis Stenosis","Cerebravascular Event",{"date":246,"type":31},{"date":318,"type":31},"2022-11-01",{"date":320,"type":20},"2026-12-31",{"name":37,"class":38},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":132,"minAge":17,"maxAge":161,"enrollmentInfo":329,"targetDuration":4,"studyType":137,"phases":4,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":340,"locationsCount":4},"100604853","a-novel-insight-into-crpc-progression-and-immune-evidence-from-single-cell-spatial-transcriptome-multi-omics-100604853","NCT07154914","A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics","Mapping Prostate Cancer Evolution and Therapy Resistance With Single-Cell Technologies","Inclusion Criteria:\n\n1. Male patients, age \\>18 and \\\u003C85 years.\n2. Histologically confirmed prostate adenocarcinoma, ductal adenocarcinoma, or intraductal carcinoma.\n3. Evidence of distant metastases by imaging (according to RECIST criteria).\n4. No prior systemic therapy for prostate cancer (no ADT or other systemic treatments).\n5. ECOG performance status 0-2 and estimated life expectancy \\>6 months.\n6. Adequate organ function as indicated by:\n\n   * Hemoglobin ≥ 90 g\u002FL\n\n     * ANC ≥ 1.5 × 10\\^9\u002FL\n\n       * Platelet count ≥ 75 × 10\\^9\u002FL\n\n         * WBC ≥ 3 × 10\\^9\u002FL ⑤ Total bilirubin ≤ ULN ⑥ ALT\u002FAST ≤ 2.5 × ULN ⑦ Creatinine clearance ≥ 30 mL\u002Fmin (Cockcroft-Gault formula)\n\n           * INR ≤ 1.5 or PT \\\u003C 4 sec above ULN\n7. Ability to provide written informed consent.\n\nExclusion Criteria:\n\n1. Histological diagnosis of neuroendocrine or small-cell prostate cancer.\n2. No evidence of distant metastases on imaging.\n3. Prior systemic therapy for prostate cancer (neoadjuvant, adjuvant, or systemic).\n4. Severe endocrine, metabolic, gastrointestinal, hepatic, or renal disease (including chronic hepatitis, cirrhosis, chronic nephritis, or renal failure).\n5. History of immunodeficiency, including HIV positivity, congenital immunodeficiency, or organ transplantation.\n6. History of other malignancies (except non-melanoma skin cancer).\n7. Concurrent participation in another clinical trial.\n8. Inability to provide clinical information or anticipated loss to follow-up.\n9. Any condition deemed unsuitable for study participation by the investigator.",{"count":330,"type":20},396,"This study will follow patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) combined with different treatments. Prostate cancer is a common cancer in men, and many patients in China are diagnosed at an advanced stage. While ADT alone has been the standard treatment, most patients eventually progress to castration-resistant disease.\n\nNew medicines such as abiraterone, enzalutamide, apalutamide, darolutamide, and chemotherapy like docetaxel have shown survival benefits when added to ADT. This study aims to observe how different ADT-based combinations work in real-world practice and whether genetic differences affect outcomes.\n\nAbout 396 patients will be enrolled and followed until disease progression or death. The results will help identify which treatments are most effective and guide more personalized care for men with advanced prostate cancer.",[333],"Metastatic Hormone-Sensitive Prostate Cance","2025-08-27",{"date":336,"type":31},"2025-09-04",{"date":338,"type":20},"2025-09-01",{"date":62,"type":20},{"name":37,"class":38},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":74,"enrollmentInfo":347,"targetDuration":4,"studyType":21,"phases":348,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":39},"100604700","the-impact-of-beta-band-transcranial-alternating-current-stimulation-tacs-on-impulse-inhibition-in-adolescents-with-non-suicidal-self-injury-100604700","NCT07152925","The Impact of Beta-band Transcranial Alternating Current Stimulation (tACS) on Impulse Inhibition in Adolescents With Non-suicidal Self-injury","Inclusion Criteria:\n\n* 1\\) Meet the proposed diagnostic criteria for non-suicidal self-injury (NSSI) in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), with ≥5 documented self-injury episodes and at least one incident within the past month as assessed by the Adolescent Non-Suicidal Self-Injury Assessment Questionnaire (ANSAQ); 2) Aged 12-18 years; 3) Right-handed; 4) Possess formal education experience sufficient to comprehend experimental protocols; 5) Normal or corrected-to-normal binocular visual acuity; 6) Voluntarily participate with legal guardians providing written informed consent.\n\nExclusion Criteria:\n\n* 1\\) Montreal Cognitive Assessment (MoCA) score \\\u003C 26; 2) History of suicide attempt(s); 3) Medical history of epilepsy, brain surgery, intracranial tumors, metal implants in the skull, or clinically significant head trauma; 4) History of substance use disorder, brain injury, severe somatic diseases, psychiatric disorders, or comorbid DSM-5 psychiatric conditions; 5) Prior receipt of transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or repetitive transcranial magnetic stimulation (rTMS) within the past 3 months",{"count":105,"type":20},[23],"This clinical trial aims to determine whether beta-band transcranial alternating current stimulation (tACS) can improve impulse inhibition in adolescents with non-suicidal self-injury (NSSI) and to evaluate its safety. The primary questions it seeks to answer are:\n\n* Can beta-band tACS significantly reduce the frequency of self-injury and scores on impulsivity scales in adolescents with NSSI?\n* What discomfort or medical issues may participants experience during tACS intervention?\n\nResearchers will compare beta-band tACS with sham stimulation (a procedure that mimics the real stimulation without delivering effective current) to verify its efficacy.\n\nParticipants will:\n\n* Receive two sessions of either tACS or sham stimulation daily, spaced 4 hours apart, for 7 consecutive days (14 sessions in total).\n* Undergo scale assessments, behavioral tasks, and eye-tracking tests before and after the intervention.\n* Record any self-injury episodes and adverse reactions, with continuous monitoring and psychological support provided by a professional team.",[351,80],"Depression Disorders",[353,82,83],"Depression","2025-08-26",{"date":356,"type":31},"2025-09-03",{"date":358,"type":31},"2025-03-01",{"date":360,"type":20},"2026-05-31",{"name":37,"class":38},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":16,"minAge":369,"maxAge":233,"enrollmentInfo":370,"targetDuration":4,"studyType":21,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":4},"100596424","effectiveness-of-a-digital-behavioral-intervention-program-for-overweight-and-obese-patients-100596424","NCT07045272","Effectiveness of a Digital Behavioral Intervention Program for Overweight and Obese Patients","Study on the Construction and Effectiveness of a Digital Behavioral Intervention Program for Overweight and Obese Patients Prior to Assisted Reproductive Technology(ART)Treatment","Inclusion Criteria:\n\n1. Fulfilling the World Health Organization diagnostic criteria for infertility, defined as failure to achieve or sustain a clinical pregnancy after ≥1 year of regular unprotected sexual intercourse among couples of reproductive age;\n2. patients aged 20-40 years seeking assisted reproductive technology (ART) treatment;\n3. Body mass index (BMI) \\>=24 kg\u002Fm²;\n4. Willingness to undergo randomization;\n5. Absence of significant comorbidities (e.g., uncontrolled hypertension, diabetes mellitus, malignancies);\n6. Commitment to participate in and complete the intervention protocol.\n\nExclusion Criteria:\n\n1. History of major systemic diseases (e.g., cardiovascular disorders, chronic respiratory diseases) or psychiatric disorders (e.g., schizophrenia, major depressive disorder);\n2. Current or prior participation in other clinical trials within the past 3 months;\n3. Medical contraindications to physical exercise (e.g., severe osteoarthritis, uncontrolled arrhythmias);\n4. Previous weight-loss interventions, including pharmacological therapy (e.g., orlistat, liraglutide) or bariatric surgery.","20 Years",{"count":76,"type":20},[23],"This study applied digital technology to a comprehensive lifestyle intervention strategy to design a digital behavioural intervention programme suitable for weight reduction in overweight obese infertile patients in China, and assessed its intervention effect through a randomised controlled trial.The main questions it aims to answer are:\n\n1\\) Design and implement a digital behavioural weight loss intervention programme; 2) Evaluate the impact of digital behavioural interventions on weight loss outcomes and health outcomes.\n\nParticipants will be randomly assigned to a control group and an intervention group.\n\nThe control group will receive only routine health education and the intervention group will receive an 8-week digital behavioural intervention. At the end of the intervention, the follow-up period will be one year for reproductive outcomes.",[374],"Overweight or Obesity","2025-06-21",{"date":377,"type":31},"2025-07-01",{"date":379,"type":20},"2025-07-10",{"date":381,"type":20},"2027-08-20",{"name":37,"class":38},{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":16,"minAge":233,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":21,"phases":392,"briefSummary":393,"conditions":394,"keywords":397,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":39},"100545541","the-efficacy-and-safety-of-precision-repetitive-transcranial-magnetic-stimulation-in-alleviating-motor-symptom-in-parkinsons-disease-100545541","NCT06383247","The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease","A Randomized, Double-blind, Multicenter, Placebo-controlled Trial (PRESS-PD)","Inclusion Criteria:\n\n1. Age ≥ 40 years old;\n2. Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))\\[1\\];\n3. Have no history of drug adjustment within 4 weeks before treatment and the entire study period;\n4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4;\n5. MMSE ≥22，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.\n\nExclusion Criteria:\n\n1. Previously head MRI\u002FCT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above);\n2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);\n3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;\n4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.\n5. The person has a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;\n6. Diagnosed with a neuropsychiatric disorder other than PD\n7. Have a history of drug abuse or drug use;\n8. Participants in any clinical trial within the previous 6 month;\n9. Pregnant\u002Flactating women or subjects (including men) who have a birth plan within 6 months;\n10. Other conditions deemed unsuitable for inclusion by the investigator.",{"count":391,"type":20},290,[23],"Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.",[239,395,396],"Transcranial Magenetic Stimualtion","Supplementary Motor Area",[239,398,399],"transcranial magenetic stimualtion","supplementary motor area","2025-06-14",{"date":402,"type":31},"2025-06-17",{"date":404,"type":31},"2024-12-06",{"date":406,"type":20},"2028-12-31",{"name":37,"class":38},{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":16,"minAge":233,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":21,"phases":416,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":39},"100562783","the-efficacy-of-olfactory-training-intervention-on-olfactory-and-other-non-motor-symptoms-in-pd-100562783","NCT06607653","The Efficacy of Olfactory Training Intervention on Olfactory and Other Non-motor Symptoms in PD","Inclusion Criteria:\n\n1. PD was diagnosed according to the criteria of Movement Disorders and Parkinson Disease Group of Chinese Society of Neurology of Chinese Medical Association.\n2. Olfactory score was 1 standard deviation lower than the corresponding age norm;\n3. no medication plan in the past four weeks or no change in medication plan in the past four weeks, which can be maintained until the end of the experiment; 4.40-75 years old, with normal vision, hearing and language understanding and expression ability;\n\n5.Good cooperation of patients\n\nExclusion Criteria:\n\n1. Parkinson\\'s syndrome and Parkinson\\'s plus syndrome caused by cerebrovascular disease, encephalitis, trauma, drugs, etc.;\n2. Neuropsychiatric diseases that may affect the sense of smell, such as depression, anxiety, schizophrenia, etc.;\n3. History of nasal disease or surgery, such as rhinitis, sinusitis, nasal septum deviation, etc. Upper respiratory tract infection in the past 3 weeks;\n4. Long-term smoking and occupations that inhale chemical irritants for a long time.","75 Years",{"count":208,"type":20},[23],"To explore the efficacy of olfactory training on olfactory and other non-motor symptoms in PD.",[239,419,420],"Olfactory Disorder","Olfactory Training",[239,419,422],"Olfactory training","2024-09-20",{"date":425,"type":31},"2024-09-23",{"date":427,"type":20},"2024-09-25",{"date":429,"type":20},"2025-04-10",{"name":37,"class":38},{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":11,"sex":16,"minAge":233,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":21,"phases":439,"briefSummary":393,"conditions":440,"keywords":441,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":448,"locationsCount":4},"100560909","the-efficacy-of-repetitive-transcranial-magnetic-stimulation-in-parkinson39s-diseasea-randomized-double-blind-multicenter-placebo-controlled-trial-100560909","NCT06583278","The Efficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease：A Randomized, Double-blind, Multicenter, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Age ≥40 years old\n2. Meet Movement Disorder Society standards;\n3. Have no history of drug adjustment within 4 weeks before and during treatment;\n4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4\n5. MMSE ≥24，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.\n\nExclusion Criteria:\n\n1. Head MRI\u002FCT ruled out focal brain injury or severe leukoencephalopathy (Fazekas grade 3);\n2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);\n3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;\n4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.\n5. The person or first-degree relatives have a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;\n6. Diagnosed with a neuropsychiatric disorder other than PD\n7. Have a history of drug abuse or drug use;\n8. Participants in any clinical trial within the previous 6 month;\n9. Pregnant\u002Flactating women or subjects (including men) who have a birth plan within 6 months;\n10. Other conditions deemed unsuitable for inclusion by the investigator.",{"count":438,"type":20},312,[23],[239,395,396],[239,395,396],"2024-09-01",{"date":444,"type":31},"2024-09-04",{"date":446,"type":20},"2024-11-01",{"date":152,"type":20},{"name":37,"class":38},{"id":450,"slug":451,"hasResults":11,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":161,"enrollmentInfo":455,"targetDuration":4,"studyType":21,"phases":456,"briefSummary":457,"conditions":458,"keywords":462,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":39},"100559516","effect-of-transcranial-alternating-current-stimulationtacs-for-early-alzheimers-disease-100559516","NCT06565143","Effect of Transcranial Alternating Current Stimulation(tACS) for Early Alzheimer's Disease","Inclusion Criteria:\n\n1. Subject diagnosed with early Alzheimer's disease or related diseases according to NIA-AA criteria.\n2. Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia.\n3. CDR score ≤ 2.\n4. Subject under treatment by IAChE for at least 3 months.\n5. psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months.\n\nExclusion Criteria:\n\n1. CDR \\> 2\n2. Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).\n3. History of head injury,stroke,or other neurologic disease.\n4. Organic brain defects on T1 or T2 images.\n5. History of seizures or unexplained loss of consciousness.\n6. Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.\n7. Family history of medication refractory epilepsy.\n8. History of substance abuse within the last 6 months.",{"count":208,"type":20},[23],"To investigate the clinical effect neural mechanism of transcranial alternating current stimulation in early Alzheimer's disease",[459,460,461],"Transcranial Alternating Current Stimulation","Electroencephalography","Early Alzheimer's Disease",[459,460,463,461,464,465],"Neuropsychology","Alzheimer's Disease Assessment Scale-Cognitive Subscale","Working Memory","2024-08-19",{"date":468,"type":31},"2024-08-21",{"date":470,"type":31},"2024-03-01",{"date":472,"type":20},"2026-07-01",{"name":37,"class":38},{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":11,"sex":16,"minAge":233,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":21,"phases":481,"briefSummary":482,"conditions":483,"keywords":484,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":490,"leadSponsor":492,"locationsCount":39},"100557813","an-open-label-study-on-the-clinical-efficacy-of-rtms-intervention-in-pd-100557813","NCT06542991","An Open-label Study on the Clinical Efficacy of rTMS Intervention in PD",{"count":480,"type":20},20,[23],"To demonstrate that intervention targeting the supplementary motor area (SMA) using precise navigation positioning can effectively improve motor symptoms in patients with Parkinson's disease.",[112,239,396],[112,239,485],"Supplementary motor area","2024-08-03",{"date":488,"type":31},"2024-08-07",{"date":442,"type":20},{"date":491,"type":20},"2025-03-31",{"name":37,"class":38},{"id":494,"slug":495,"hasResults":11,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":21,"phases":502,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":512,"leadSponsor":514,"locationsCount":4},"100553342","evaluation-of-the-effectiveness-of-the-combined-psychological-resilience-and-self-efficacy-intervention-for-improving-resilience-and-self-efficacy-and-reducing-anxiety-and-depression-of-oesophageal-cancer-surgery-patients-100553342","NCT06484842","Evaluation of the Effectiveness of the Combined Psychological Resilience and Self-efficacy Intervention for Improving Resilience and Self-efficacy and Reducing Anxiety and Depression of Oesophageal Cancer Surgery Patients","A Randomised Controlled Study to Evaluate the Effectiveness of the Combined Psychological Resilience and Self-efficacy Intervention for Oesophageal Cancer Surgery Patients","Inclusion Criteria:\n\n* Diagnosed with oesophageal cancer by pathological biopsy.\n* Received surgical treatment.\n* Native Chinese speakers and age≥18 years old.\n\nExclusion Criteria:\n\n* Prior to or during the first evaluation, patients who had end-stage illnesses or other chronic ailments including kidney failure, heart failure, etc..\n* Undergoing further supplementary therapies such as neoadjuvant chemotherapy or radiotherapy.\n* Undergoing other systematic psychological therapies.\n* Possess a background of psychopathy or cognitive problems.\n* Patients\\' baseline anxiety and depression subscale scores are less than 8 points each.",{"count":501,"type":20},123,[23],"The goal of this clinical trial is to evaluate the effectiveness of the combined psychological resilience and self-efficacy intervention in oesophageal cancer surgery patients. The main question it aims to answer is:\n\nIs the combined psychological resilience and self-efficacy intervention program more effective than the single psychological resilience intervention in improving psychological resilience and self-efficacy and reducing anxiety and depression in patients undergoing oesophageal cancer surgery? Researchers will compare the combined psychological resilience and self-efficacy intervention program to the single psychological resilience intervention and routine care to see if the combined intervention can improve psychological resilience and self-efficacy and reduce anxiety and depression in oesophageal cancer surgery patients.\n\nParticipants will receive the combined psychological resilience and self-efficacy intervention program in the combined intervention group, the single psychological resilience intervention in the single intervention group and routine care in the control group.",[505],"Esophageal Cancer",[507],"Esophageal Neoplasms; Resilience, Psychological; Self Efficacy","2024-07-01",{"date":510,"type":31},"2024-07-03",{"date":508,"type":20},{"date":513,"type":20},"2025-06-01",{"name":37,"class":38},{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":522,"targetDuration":4,"studyType":21,"phases":523,"briefSummary":524,"conditions":525,"keywords":530,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":39},"100534679","high-definition-transcranial-direct-current-stimulation-hd-tdcs-for-refractory-epilepsy-100534679","NCT06241963","High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy","The Efficacy, Safety and Mechanism of High Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Refractory Epilepsy","Inclusion Criteria:\n\n* Clinical diagnosis of refractory epilepsy\n* Right-handed and aged 18-50 years old and primary school education or above;\n* No major neurological or mental illness, no head injury, alcohol dependence or drug dependence;\n* During the experiment, the subjects did not smoke, drink, get sick and take psychotropic drugs, and there were no major life events that caused mood changes.\n\nExclusion Criteria:\n\n* organic brain injury, neurological diseases or serious physical diseases;\n* Have a history of substance abuse and drug dependence, or have used antipsychotic drugs in the past three months, and have serious suicidal tendencies;\n* There are contraindications for MRI or EEG or transcranial magnetic stimulation.",{"count":76,"type":20},[23],"To observe the clinical effect and safety of transcranial electrical stimulation on patients with refractory epilepsy before and after treatment and analyze its therapeutic mechanism.",[526,527,528,529,112],"Transcranial Direct Current Stimulation","EEG","Functional Magnetic Resonance Imaging","Refractory Epilepsy",[529,528,527,531],"Transcranial magnetic stimulation","2024-02-15",{"date":534,"type":31},"2024-02-20",{"date":536,"type":20},"2024-02-12",{"date":538,"type":20},"2026-06-30",{"name":37,"class":38},{"id":541,"slug":542,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":548,"targetDuration":4,"studyType":21,"phases":550,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":39},"100510120","early-phase-1-efficacy-of-na-combined-with-peg-ifn-2b-in-the-continuous-versus-pulsed-treatment-of-patients-with-chronic-hepatitis-b-100510120","NCT05922306","Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B","A Multicenter, Prospective Cohort Study: Efficacy of NA Combined With PEG-IFN-α2b Continuous Versus Pulsed Therapy for 96 Weeks in Patients With Chronic Hepatitis B.","EPCP","Inclusion Criteria:\n\n1. Age 18 to 60 years, both sexes (both 18 and 60 years)\n2. HBsAg positive for more than 6 months;\n3. NAs treated patients on continuous NA therapy for more than 6 months with HBsAg ≥ 1500 IU\u002Fml and HBV-DNA \\\u003C 500 IU\u002Fml at enrolment;\n4. Primary treated patients with surface antigen \\>1500 IU, unlimited E antigen and unlimited HBV DNA at enrolment, meeting the treatment indications of the 2019 edition of the guidelines for the prevention and treatment of chronic hepatitis B.\n5. negative urine or serum pregnancy test within 24 hours prior to the first dose (for women of childbearing age)\n\nExclusion Criteria:\n\n1. Combined active hepatitis A, C, D, E and\u002For HIV infection;\n2. Patients who are on future and intend to continue to use tibivudine\n3. methaemoglobin greater than 100ng\u002Fml at screening; or methaemoglobin that has not remained stable for 3 months prior to the trial and\u002For liver imaging suggestive of liver tumours;\n4. decompensated liver disease (Child-Pugh score ≥ 7), meaning that patients will be excluded if one of the following is met: prolonged prothrombin time ≥ 3 seconds, serum bilirubin \\> 34umol\u002FL, history of hepatic encephalopathy, history of oesophageal variceal bleeding, ascites;\n5. pregnant or lactating women or patients with planned pregnancy during the study period and unwilling to use contraception\n6. Neutrophil count \\\u003C 1.5 x 10\\^9\u002FL or platelet count \\\u003C 90 x 10\\^9\u002FL and creatinine \\> 1.5 ULN\n7. History of severe psychiatric illness, especially depression. Major psychosis defined as major depressive disorder or psychosis, suicide attempts, hospitalisation for psychosis or incapacity for a period of time due to psychosis;\n8. history of immune-mediated disease (e.g. inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic anaemia, scleroderma, severe psoriasis, rheumatoid arthritis) or abnormally elevated levels of autoimmune antibodies\n9. Patients with severe combined diseases of the heart, lungs, kidneys, brain, blood and other vital organs, combined with other malignancies\n10. History of severe epilepsy or current treatment with anti-epileptic drugs. Unstable control of diabetes mellitus, hypertension, thyroid disease, etc. Patients with a history of severe retinopathy or as indicated by other evidence of retinopathy;\n11. History of any organ transplantation and existing functional grafts (except corneal or hair transplants);\n12. Patients who are allergic to interferon and its drug components and who, in the judgment of the investigator, are unsuitable for interferon application\n13. Patients who, in the opinion of the investigator, are not suitable for participation in this study.",{"count":549,"type":20},1084,[551],"EARLY_PHASE1","Previous studies have shown that there are alterations in the number and affinity of interferon receptors during interferon therapy and that such alterations recover to varying degrees some time after the end of treatment. It can be conjectured that the rest period of pulsed therapy facilitates the recovery of type I interferon receptors and thus the next round of IFN therapy compared to a continuous regimen of interferon.",[554],"Hepatitis B, Chronic","2023-06-24",{"date":557,"type":31},"2023-06-28",{"date":559,"type":20},"2023-07",{"date":561,"type":20},"2027-12",{"name":37,"class":38},""]